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ABSTRACT
INTRODUCTION: Clozapine is an atypical antipsychotic, treatment of choice for patients unresponsive 
to, or intolerant of other antipsychotic drugs. While most of the adverse effects of clozapine are well dis-
cussed in the literature, clozapine-induced parotitis emerges as an uncommon complication, which clini-
cians should be aware of.
AIM: The aim of this report is, by illustrating a case of clozapine-induced parotitis and reviewing the lit-
erature on the topic, to bring awareness of the occurrence of this potential adverse effect of clozapine treat-
ment.
CASE PRESENTATION: Due to poor response to several adequate trials with different antipsychotic 
medications a 57-year-old female with schizoaffective disorder was initiated on clozapine in 2008. The psy-
chiatric condition of the patient notably improved in the following years. In 2016, after a decrease in her psy-
chotropic therapy, the patient was hospitalized, and while restoring treatment with clozapine and divalpro-
ex she complained of increased salivation combined with painful bilateral parotid enlargement. The diag-
nosis of clozapine-induced parotitis was suggested. The medical condition had a favorable outcome within 
five days after administration of symptomatic medication.
CONCLUSION: Adherence to drug treatment in psychiatric patients can be significantly improved if pa-
tients are well informed about the potential adverse effects of the administered medications and if the cli-
nicians recognize and try to resolve them. Monitoring both common and rare adverse effects of clozapine 
treatment will give patients a chance of better therapy management.
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INTRODUCTION
Clozapine is a unique molecule with respect to 
both beneficial and adverse effects. Introduced in the 
1970s, it was withdrawn a few years later due to fa-
tal cases of agranulocytosis. However, recently af-
ter that, it was “rediscovered” with the recognition 
of the most effective atypical antipsychotic and treat-
ment of choice in refractory schizophrenia, which is 
estimated to affect up to 30% of all patients suffer-
48 Scripta Scientifica Medica, 2018;50(2):47-51Medical University of Varna
Transient Parotitis in the Course of Clozapine Treatment: A Case Report and Review of the Literature
her psychiatric symptoms but complained of painful 
bilateral parotid swelling combined with increased 
salivation.  The patient was apyretic, with physiolog-
ical variables within normal range. Once a viral or 
bacterial etiology was ruled out, Mrs P. was seen by a 
maxillofacial specialist and parotitis was confirmed 
by ultrasound. Biperiden was added to the treatment 
and the patient was closely observed. The medical 
condition had a favorable outcome within five days.
DISCUSSION
Our case report illustrates bilateral parotitis 
after clozapine dose adjustment in the course of an 
eight-year-long clozapine treatment in a patient ex-
periencing hypersalivation.
The swelling and inflammation of one or both 
salivary glands is considered as parotitis. While uni-
lateral parotitis is attributed mainly to ductal ob-
struction, the inflammation and swelling of both pa-
rotid glands is more likely to reflect systemic causes 
(5). Drug-induced parotitis is a very uncommon ad-
verse reaction, which may be caused by different 
drugs (4). It is among the least prominent side effects 
observed in patients on clozapine treatment (6). 
The methods proposed, evaluating the causal 
role of a drug treatment in the occurrence of an ad-
verse medical event, can be generally classified under 
three large categories: expert judgement, operation-
al algorithms and probabilistic methods (7). The sys-
tem of assessment introduced by the World Health 
Organization Collaborating Centre for Internation-
al Drug Monitoring, the Uppsala Monitoring Centre 
(WHO–UMC), and the Naranjo Probability Scale, 
both outlining a relatively simple methodology, are 
among the most widely accepted methods of causal-
ity assessment of adverse drug reactions used in clin-
ical practice. Moreover, the above scales proved to 
be structured, transparent and consistent (8, 9). The 
WHO-UMC system is a joint assessment tool evalu-
ating both the clinico-pharmacological details of the 
case history and the quality of the medical records 
documenting the case. This method gives guidance 
to the general assessment criteria, helping to select 
one category over another (9,10). When assessed un-
der the WHO–UMC causality categories, our case 
was identified in the “probable/likely” category. The 
probability that a causal link exists between an un-
toward reaction and drug therapy is classified by the 
ing from schizophrenia (1,2). While some of the ad-
verse effects of clozapine as weight gain and metabol-
ic abnormalities, possible hematological toxicity, risk 
of sedation and sialorrhea are well discussed in the 
literature (3), clozapine-associated parotitis emerg-
es as an uncommon complication, which clinicians 
should be aware of (4).
Described is the clinical case of a 57-year-old 
woman who developed parotitis in the course of 
eight-year-long clozapine treatment. Patient’s verbal 
consent for the case report was obtained.
CASE PRESENTATION
Mrs A.P. is a widow with two grown-up daugh-
ters. The history of her schizoaffective disorder dates 
back to 1975 when it presented with a depressive epi-
sode. A year later she was diagnosed with a manic ep-
isode accompanied with some disorder of thinking 
and mood-incongruent delusions. Her course over 
the next 30 years has been marked by annual recur-
rences, either manic or depressive in nature, most of 
them associated with mood-incongruent psychotic 
symptoms. Although Mrs P. has generally done well 
between episodes in the first years of her illness, she 
was unable to keep a permanent job and claimed for 
disability support pension. Her psychiatric condition 
deteriorated after 2005, marked by increased fre-
quency and severity of her schizoaffective episodes. 
Following a hospital admission during which her 
psychiatric symptoms responded only slightly to two 
well-conducted antipsychotic trials with haloperi-
dol and quetiapine, in August 2008 the patient was 
initiated on clozapine, which was never increased 
to more than 200 mg/day. Clozapine was augment-
ed with 1000 mg/day divalproex. Over the next years 
Mrs P. experienced notable improvement and seemed 
compliant with treatment. She reported higher self-
esteem and better social interactions.  She reunited 
with her family, started living with one of her daugh-
ters and helped with the household chores. She also 
managed a part-time job. In the autumn of 2016, fol-
lowing a decrease in the dose of clozapine, Mrs P. was 
hospitalized for a relapse of her schizoaffective disor-
der with depressive and mood-incongruent paranoid 
symptoms. She was treated with 150 mg/day clozap-
ine and 1000 mg/day divalproex was reinitiated to-
gether with 10 mg/day escitalopram. Nineteen days 
later, Mrs P. exhibited substantial improvement of 
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Naranjo criteria based on a list of weighted questions 
examining aspects like the time relation to the ad-
ministration of the medication and the detection and 
progression of the adverse event, alternative causes 
for its occurrence, blood levels of the administered 
drugs, and previous patient experience with them. 
Recently the Naranjo adverse drug reaction proba-
bility scale has been utilized to evaluate causality for 
drug-induced parotitis (4). Scoring 6 on the parotitis-
specific criteria modified Naranjo probability scale, 
the swelling of the salivary glands of the patient in 
our case report was probably caused by clozapine. 
We searched Medline, Scopus and Science Di-
rect for articles relevant to clozapine-induced paroti-
tis. No time frame restrictions were placed for Eng-
lish language articles. Fifteen reports were found, de-
scribing 21 patients who developed parotitis after 
clozapine administration (Table 1). In most cases clo-
zapine-induced parotitis developed shortly after ini-
tiation of the drug or as a result of increased doses of 
clozapine due to a new relapse. In some occasions ac-
celerated titration was present. There were unilater-
al and bilateral cases, cases that were recurrent or oc-
curred under one occasion. In most reports there was 
a relation between sialorrhea and clozapine-induced 
parotitis albeit a continuing debate exists in the lit-
erature over the exact cause-effect relation. In some 
cases co-occurring eosinophilia was present. 
Whether sialorrhea generally precedes or fol-
lows clozapine-induced parotitis is still to be deter-
mined (24). After all, the main pathophysiological 
hypotheses trying to explain clozapine-induced par-
otitis are related to cell-mediated immune activation 
and inflammation. Hinze-Selch et al. (1996) pro-
posed the immunologically mediated mechanism, 
suggesting that peripheral blood mononuclear cells 
sensitized to clozapine are associated with the devel-
opment of sialadenitis, causing a swelling of the pa-
rotid glands (15). Vasile and Steingard (1995) hypoth-
esized that the anticholinergic properties of clozap-
ine may lead to thickening and stasis of saliva with 
precipitation of calcium salts leading to sialolithi-
Reference N patients CLZ dose (mg/day)
Modified 
NPS score UL/BL Hypersalivation
Martin SD (1993) (11) 1 400-600 3 BL YES
Robinson D et al. (1995) (12) 2 300-600 4 BL YES
Vasile JS and  Steingard S (1995) (13) 4 25-150 N/A BL NO
Davé M (1995) (14) 2 600-675 3 UL YES
Hinze-Selch D et al. (1996) (15) 1 200 6 BL YES
Brodkin ES et al. (1996) (16) 1 200 4 BL YES
Patkar AA and Alexander RC (1996) (17) 1 175 6 BL YES
Southhall K and Fernando N (1999) (18) 1 300 3 UL YES
McKay D (2000) (19) 1 150 6 BL YES
Acosta-Armas AJ (2001) (20) 2 275-900 N/A BL YES
Immadisetty V and Agrawal P (2012) (21) 1 300 7 BL YES
Vohra A (2013) (22) 1 175 9 UL NO
Gouzien C et al. (2014) (23) 1 350-500 4 BL YES
Saguem BN et al. (2015) (24) 1 275 6 BL YES
Jerónimo J et al. (2016) (25) 1 400 5 UL YES
Our case report 1 200 6 BL YES
Table 1. Case reports of suspected clozapine induced  parotitis
CLZ - Clozapine; NPS - Naranjo Probability Scale; UL - Unilateral; BL - Bilateral
50 Scripta Scientifica Medica, 2018;50(2):47-51Medical University of Varna
Transient Parotitis in the Course of Clozapine Treatment: A Case Report and Review of the Literature
asis, consequent obstruction in the duct and final-
ly, to the swelling of the salivary glands (13). In our 
case hypersalivation was present, although it was not 
declared as a problematic side effect by the patient. 
We suggested that both described pathophysiological 
mechanisms were involved in the development of the 
bilateral swelling of the parotid glands in our patient, 
so that biperiden was added to the treatment with a 
favorable outcome.
CONCLUSION
The swelling of the salivary glands is reported 
as a rare adverse effect of clozapine therapy and there 
could be various explanations for this: lack of aware-
ness, as there are currently no treatment require-
ments for routine examinations of salivary glands 
in patients on clozapine treatment; low reporting of 
the condition as it is easy to miss or is more often 
observed in the fields of other medical specialties or 
low incidence of the event itself. However, further re-
search will reveal more comprehensively the condi-
tion and its fundamental etiological mechanisms.
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